Overview
SCIENTIFIC SCORE
Moderately Effective
Based on 25 Researches
8.5
USERS' SCORE
Good
Based on 3 Reviews
8.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Wild Caught Fish Oil Concentrate
1250 mg
†
Total Omega-3 Fatty Acids as TG
1055 mg
†
EPA (Eicosapentaenoic Acid)
690 mg
†
DHA (Docosahexaenoic Acid)
310 mg
†
Other Omega-3 Fatty Acids
55 mg
†
Top Medical Research Studies
9
We examined how Eicosapentaenoic acid (EPA) could protect against ulcerative colitis (UC), a chronic condition that inflames the large intestine. In our research, we used acetic acid to induce UC in rats, administering oral EPA for 28 days in doses of 300 and 1000 mg/kg before the acetic acid treatment.
Our findings were quite promising. EPA appeared to significantly alleviate UC symptoms, as seen in the improved colonic health of the rats. We noted that EPA treatment not only reduced inflammation but also helped restore the balance between oxidants and antioxidants in the body. This balance is crucial for maintaining a healthy gut environment and reducing tissue damage.
Moreover, EPA led to the enhancement of protective proteins in the colon, while it suppressed markers associated with inflammation. This included reductions in substances that typically signal more inflammation, which suggests that EPA has a dual role—enhancing protective factors while diminishing harmful responses. We believe these insights highlight the potential of EPA as a therapeutic agent for managing UC more effectively.
Our findings were quite promising. EPA appeared to significantly alleviate UC symptoms, as seen in the improved colonic health of the rats. We noted that EPA treatment not only reduced inflammation but also helped restore the balance between oxidants and antioxidants in the body. This balance is crucial for maintaining a healthy gut environment and reducing tissue damage.
Moreover, EPA led to the enhancement of protective proteins in the colon, while it suppressed markers associated with inflammation. This included reductions in substances that typically signal more inflammation, which suggests that EPA has a dual role—enhancing protective factors while diminishing harmful responses. We believe these insights highlight the potential of EPA as a therapeutic agent for managing UC more effectively.
Read More
9
In our investigation, we focused on the effects of eicosapentaenoic acid (EPA) on ulcerative colitis (UC), a chronic condition characterized by inflammation in the colon. We conducted experiments using mice with dextran sodium sulfate (DSS)-induced colitis to understand how EPA might improve this condition compared to docosahexaenoic acid (DHA).
What we found was quite striking. Mice treated with high doses of EPA showed a significantly reduced severity of colitis symptoms. This improvement was linked to the presence of a stronger mucus barrier in the gut, which is essential for protecting the colon and managing interactions between the host and gut bacteria.
Additionally, we observed that EPA encouraged the production of mucin and enhanced the diversity of beneficial gut microbiota. This suggests that EPA not only helps to fortify the mucus lining of the colon but also supports a healthy balance of gut bacteria, which may further alleviate UC symptoms.
Therefore, our results highlight the potential of EPA as a promising therapeutic option for those suffering from ulcerative colitis.
What we found was quite striking. Mice treated with high doses of EPA showed a significantly reduced severity of colitis symptoms. This improvement was linked to the presence of a stronger mucus barrier in the gut, which is essential for protecting the colon and managing interactions between the host and gut bacteria.
Additionally, we observed that EPA encouraged the production of mucin and enhanced the diversity of beneficial gut microbiota. This suggests that EPA not only helps to fortify the mucus lining of the colon but also supports a healthy balance of gut bacteria, which may further alleviate UC symptoms.
Therefore, our results highlight the potential of EPA as a promising therapeutic option for those suffering from ulcerative colitis.
Read More
9
We conducted a study to figure out how eicosapentaenoic acid (EPA) affects patients with ulcerative colitis (UC), particularly its role in reducing inflammation and preventing relapse. This was a well-structured trial involving 60 participants who had stable UC therapy for at least three months. They were randomly assigned to receive either EPA in its free fatty acid form (500 mg, twice daily) or a placebo over six months.
Throughout the study, we tracked levels of calprotectin in fecal samples, a marker indicating inflammation in the intestines. Our goal was to see if EPA could lead to a significant reduction in these levels, as well as maintain remission from symptoms. The results were promising—after six months, we found that those taking EPA had lower calprotectin levels, suggesting less inflammation and contributing to fewer relapses.
Importantly, no serious side effects were reported during the study, which adds to the potential appeal of using EPA as a treatment option. Overall, our findings suggest that EPA could be a useful component in the management of UC, helping patients achieve and sustain symptom-free periods.
Throughout the study, we tracked levels of calprotectin in fecal samples, a marker indicating inflammation in the intestines. Our goal was to see if EPA could lead to a significant reduction in these levels, as well as maintain remission from symptoms. The results were promising—after six months, we found that those taking EPA had lower calprotectin levels, suggesting less inflammation and contributing to fewer relapses.
Importantly, no serious side effects were reported during the study, which adds to the potential appeal of using EPA as a treatment option. Overall, our findings suggest that EPA could be a useful component in the management of UC, helping patients achieve and sustain symptom-free periods.
Read More
Most Useful Reviews
10
No more ulcers
Excellent! I've been taking this for three years now and haven't had any more mouth ulcers. The delivery is always prompt.
Read More
9
Pain relief
Omega-3 PUFAs are effective in lowering blood cholesterol and triglycerides, and they help normalise blood pressure. They are an excellent preventive measure against cardiovascular diseases. Omega-3 also aids in healing gastric ulcers and duodenal ulcers. I noticed that a few days into treatment, the pain subsided, and my ulcer began to heal.
Read More
6
Helpful for ulcers
The benefits of consuming more fish oil are notable. The omega ratio is impressive, and the taste is not fishy. After a month of taking it, I've experienced multiple benefits, including improved sleep and regular morning bowel movements. I have also noticed a reduction in oral ulcers, and I plan to continue taking it long-term.
Read More
Medical Researches
SCIENTIFIC SCORE
Moderately Effective
Based on 25 Researches
8.5
- All Researches
9.5
We explored the potential of omega-3-acid ethyl esters, particularly docosahexaenoic acid, as a treatment for difficult-to-heal pressure ulcers and stasis dermatitis. In the cases we examined, we noted remarkable healing effects from oral administration of this supplement.
Our first case involved a young woman with paralysis who had stubborn pressure ulcers on her foot. Despite using various topical treatments, there was little improvement. However, after integrating omega-3-acid ethyl esters into her regimen, we observed significant healing in just ten weeks.
In another instance, an elderly man suffering from chronic conditions also developed stasis dermatitis characterized by painful erosive ulcers. With numerous topical treatments failing, we turned to the same omega-3 supplement and were pleased to see almost complete healing in twelve weeks.
This report highlights a potential new avenue for managing pressure ulcers and stasis dermatitis, specifically where other treatments have fallen short. Overall, our findings indicate that omega-3-acid ethyl esters could be a valuable addition to treatment plans for these challenging skin conditions.
Our first case involved a young woman with paralysis who had stubborn pressure ulcers on her foot. Despite using various topical treatments, there was little improvement. However, after integrating omega-3-acid ethyl esters into her regimen, we observed significant healing in just ten weeks.
In another instance, an elderly man suffering from chronic conditions also developed stasis dermatitis characterized by painful erosive ulcers. With numerous topical treatments failing, we turned to the same omega-3 supplement and were pleased to see almost complete healing in twelve weeks.
This report highlights a potential new avenue for managing pressure ulcers and stasis dermatitis, specifically where other treatments have fallen short. Overall, our findings indicate that omega-3-acid ethyl esters could be a valuable addition to treatment plans for these challenging skin conditions.
Read More
9
We examined how Eicosapentaenoic acid (EPA) could protect against ulcerative colitis (UC), a chronic condition that inflames the large intestine. In our research, we used acetic acid to induce UC in rats, administering oral EPA for 28 days in doses of 300 and 1000 mg/kg before the acetic acid treatment.
Our findings were quite promising. EPA appeared to significantly alleviate UC symptoms, as seen in the improved colonic health of the rats. We noted that EPA treatment not only reduced inflammation but also helped restore the balance between oxidants and antioxidants in the body. This balance is crucial for maintaining a healthy gut environment and reducing tissue damage.
Moreover, EPA led to the enhancement of protective proteins in the colon, while it suppressed markers associated with inflammation. This included reductions in substances that typically signal more inflammation, which suggests that EPA has a dual role—enhancing protective factors while diminishing harmful responses. We believe these insights highlight the potential of EPA as a therapeutic agent for managing UC more effectively.
Our findings were quite promising. EPA appeared to significantly alleviate UC symptoms, as seen in the improved colonic health of the rats. We noted that EPA treatment not only reduced inflammation but also helped restore the balance between oxidants and antioxidants in the body. This balance is crucial for maintaining a healthy gut environment and reducing tissue damage.
Moreover, EPA led to the enhancement of protective proteins in the colon, while it suppressed markers associated with inflammation. This included reductions in substances that typically signal more inflammation, which suggests that EPA has a dual role—enhancing protective factors while diminishing harmful responses. We believe these insights highlight the potential of EPA as a therapeutic agent for managing UC more effectively.
Read More
9
We explored how icosapent ethyl, a form of eicosapentaenoic acid, affects ulcerative colitis, a significant inflammatory bowel disease impacting many individuals globally. In our assessment involving 36 male Wistar rats, we divided them into six groups, including a control, those with ulcerative colitis induced by acetic acid, and various treatment groups receiving either mesalamine or different doses of icosapent ethyl.
Through this structured approach, we observed that the rats with colitis displayed higher levels of harmful substances and lower levels of protective ones. However, upon administering icosapent ethyl, we noted a remarkable reduction in the severity of the inflammation, along with improvements in several biological markers, including reduced levels of malondialdehyde and certain inflammatory cytokines. The more significant dosage of icosapent, at 300 mg/kg, produced effects similar to the widely used drug, mesalamine.
We must highlight that the beneficial effects of icosapent were partially reversed by EX527, which suggests that its protective actions may involve activation of the SIRT1 signaling pathway. Our findings point toward the potential of icosapent ethyl to be an effective treatment option for ulcerative colitis, showcasing its anti-inflammatory and antioxidant properties.
Through this structured approach, we observed that the rats with colitis displayed higher levels of harmful substances and lower levels of protective ones. However, upon administering icosapent ethyl, we noted a remarkable reduction in the severity of the inflammation, along with improvements in several biological markers, including reduced levels of malondialdehyde and certain inflammatory cytokines. The more significant dosage of icosapent, at 300 mg/kg, produced effects similar to the widely used drug, mesalamine.
We must highlight that the beneficial effects of icosapent were partially reversed by EX527, which suggests that its protective actions may involve activation of the SIRT1 signaling pathway. Our findings point toward the potential of icosapent ethyl to be an effective treatment option for ulcerative colitis, showcasing its anti-inflammatory and antioxidant properties.
Read More
9
Long-chain fatty acids and ulcers
We set out to understand how different types of fatty acids might affect the development and severity of gastric ulcers in fit Thoroughbred horses. Our research involved 13 horses undergoing strenuous training, and we assessed their gastric health before and after three months of supplementation with two types of polyunsaturated fatty acids.
The horses completed a standardized exercise test to simulate the stress of racing. We specifically looked at the impact of long-chain polyunsaturated fatty acids (like eicosapentaenoic acid) found in fish oil, compared to short-chain fatty acids derived from a blend of corn and flax oil.
We observed that the long-chain fatty acid supplementation resulted in higher levels of important fatty acids, including eicosapentaenoic acid, and was linked to a reduced incidence and severity of gastric ulcers. This suggests that eicosapentaenoic acid may play a beneficial role in gastric health for high-performance horses.
However, since our findings were based on a blend of various fatty acids, isolating the specific effects of eicosapentaenoic acid on ulcers required further investigation. Thus, while our study indicates a promising trend, more research will be essential to explore this area thoroughly.
The horses completed a standardized exercise test to simulate the stress of racing. We specifically looked at the impact of long-chain polyunsaturated fatty acids (like eicosapentaenoic acid) found in fish oil, compared to short-chain fatty acids derived from a blend of corn and flax oil.
We observed that the long-chain fatty acid supplementation resulted in higher levels of important fatty acids, including eicosapentaenoic acid, and was linked to a reduced incidence and severity of gastric ulcers. This suggests that eicosapentaenoic acid may play a beneficial role in gastric health for high-performance horses.
However, since our findings were based on a blend of various fatty acids, isolating the specific effects of eicosapentaenoic acid on ulcers required further investigation. Thus, while our study indicates a promising trend, more research will be essential to explore this area thoroughly.
Read More
9
Eicosapentaenoic acid aids ulcer healing
We set out to explore the effects of eicosapentaenoic acid (EPA), a key ingredient in a marine oil supplement called LIPINOVA, on wound healing in diabetic mice. This study focused on chronic inflammation, a common issue in type 2 diabetes that often hinders the healing of ulcers.
To understand how EPA influences healing, we applied LIPINOVA to wounds created in test mice. We observed that this marine oil not only helped in closing the wounds faster but also reduced pro-inflammatory macrophages—potentially harmful immune cells that can slow down healing. Additionally, the oil encouraged better blood vessel formation and helped to balance macrophage polarization, transitioning from the inflammatory type (Mφ1) to the healing type (Mφ2).
Our findings highlight the promising role of EPA-rich marine oil in improving wound healing for diabetic patients. With its unique ability to resolve inflammation and speed up tissue repair, LIPINOVA may serve as a valuable therapeutic option for treating diabetic ulcers.
To understand how EPA influences healing, we applied LIPINOVA to wounds created in test mice. We observed that this marine oil not only helped in closing the wounds faster but also reduced pro-inflammatory macrophages—potentially harmful immune cells that can slow down healing. Additionally, the oil encouraged better blood vessel formation and helped to balance macrophage polarization, transitioning from the inflammatory type (Mφ1) to the healing type (Mφ2).
Our findings highlight the promising role of EPA-rich marine oil in improving wound healing for diabetic patients. With its unique ability to resolve inflammation and speed up tissue repair, LIPINOVA may serve as a valuable therapeutic option for treating diabetic ulcers.
Read More
User Reviews
USERS' SCORE
Good
Based on 3 Reviews
8.5
- All Reviews
- Positive Reviews
- Negative Reviews
10
No more ulcers
Excellent! I've been taking this for three years now and haven't had any more mouth ulcers. The delivery is always prompt.
Read More
9
Pain relief
Omega-3 PUFAs are effective in lowering blood cholesterol and triglycerides, and they help normalise blood pressure. They are an excellent preventive measure against cardiovascular diseases. Omega-3 also aids in healing gastric ulcers and duodenal ulcers. I noticed that a few days into treatment, the pain subsided, and my ulcer began to heal.
Read More
6
Helpful for ulcers
The benefits of consuming more fish oil are notable. The omega ratio is impressive, and the taste is not fishy. After a month of taking it, I've experienced multiple benefits, including improved sleep and regular morning bowel movements. I have also noticed a reduction in oral ulcers, and I plan to continue taking it long-term.
Read More
Frequently Asked Questions
9
Pain relief
Omega-3 PUFAs are effective in lowering blood cholesterol and triglycerides, and they help normalise blood pressure. They are an excellent preventive measure against cardiovascular diseases. Omega-3 also aids in healing gastric ulcers and duodenal ulcers. I noticed that a few days into treatment, the pain subsided, and my ulcer began to heal.
6
Helpful for ulcers
The benefits of consuming more fish oil are notable. The omega ratio is impressive, and the taste is not fishy. After a month of taking it, I've experienced multiple benefits, including improved sleep and regular morning bowel movements. I have also noticed a reduction in oral ulcers, and I plan to continue taking it long-term.
10
No more ulcers
Excellent! I've been taking this for three years now and haven't had any more mouth ulcers. The delivery is always prompt.
8
We evaluated how eicosapentaenoic acid (EPA), a type of omega-3 fatty acid, may assist in preventing peptic ulcer disease (PUD). The research employed a Mendelian randomization approach, which used specific genetic variants linked to plasma levels of omega-3 PUFAs as natural experiments. This method allowed us to draw conclusions without the biases present in typical observational studies.
Our findings indicated a significant relationship between higher plasma levels of total omega-3 PUFAs and a lower risk of developing PUD. Specifically for EPA, we observed an odds ratio of 0.81, suggesting that for every standard deviation increase in plasma EPA, there may be a reduced likelihood of ulcer development. This points toward EPA being a potentially beneficial player in ulcer prevention.
However, it’s important to note that while we saw promising results for EPA and other marine-based omega-3s such as DPA and DHA, the same could not be said for alpha-linolenic acid, another omega-3. This specific plant-derived fatty acid did not show any significant association with PUD risk. Overall, the research suggests that increasing marine-derived omega-3 intake, particularly EPA, may provide a viable strategy for reducing the risk of peptic ulcers, while the role of plant-based omega-3s remains unclear.
Our findings indicated a significant relationship between higher plasma levels of total omega-3 PUFAs and a lower risk of developing PUD. Specifically for EPA, we observed an odds ratio of 0.81, suggesting that for every standard deviation increase in plasma EPA, there may be a reduced likelihood of ulcer development. This points toward EPA being a potentially beneficial player in ulcer prevention.
However, it’s important to note that while we saw promising results for EPA and other marine-based omega-3s such as DPA and DHA, the same could not be said for alpha-linolenic acid, another omega-3. This specific plant-derived fatty acid did not show any significant association with PUD risk. Overall, the research suggests that increasing marine-derived omega-3 intake, particularly EPA, may provide a viable strategy for reducing the risk of peptic ulcers, while the role of plant-based omega-3s remains unclear.
9
In our investigation, we focused on the effects of eicosapentaenoic acid (EPA) on ulcerative colitis (UC), a chronic condition characterized by inflammation in the colon. We conducted experiments using mice with dextran sodium sulfate (DSS)-induced colitis to understand how EPA might improve this condition compared to docosahexaenoic acid (DHA).
What we found was quite striking. Mice treated with high doses of EPA showed a significantly reduced severity of colitis symptoms. This improvement was linked to the presence of a stronger mucus barrier in the gut, which is essential for protecting the colon and managing interactions between the host and gut bacteria.
Additionally, we observed that EPA encouraged the production of mucin and enhanced the diversity of beneficial gut microbiota. This suggests that EPA not only helps to fortify the mucus lining of the colon but also supports a healthy balance of gut bacteria, which may further alleviate UC symptoms.
Therefore, our results highlight the potential of EPA as a promising therapeutic option for those suffering from ulcerative colitis.
What we found was quite striking. Mice treated with high doses of EPA showed a significantly reduced severity of colitis symptoms. This improvement was linked to the presence of a stronger mucus barrier in the gut, which is essential for protecting the colon and managing interactions between the host and gut bacteria.
Additionally, we observed that EPA encouraged the production of mucin and enhanced the diversity of beneficial gut microbiota. This suggests that EPA not only helps to fortify the mucus lining of the colon but also supports a healthy balance of gut bacteria, which may further alleviate UC symptoms.
Therefore, our results highlight the potential of EPA as a promising therapeutic option for those suffering from ulcerative colitis.
9
We conducted a study to figure out how eicosapentaenoic acid (EPA) affects patients with ulcerative colitis (UC), particularly its role in reducing inflammation and preventing relapse. This was a well-structured trial involving 60 participants who had stable UC therapy for at least three months. They were randomly assigned to receive either EPA in its free fatty acid form (500 mg, twice daily) or a placebo over six months.
Throughout the study, we tracked levels of calprotectin in fecal samples, a marker indicating inflammation in the intestines. Our goal was to see if EPA could lead to a significant reduction in these levels, as well as maintain remission from symptoms. The results were promising—after six months, we found that those taking EPA had lower calprotectin levels, suggesting less inflammation and contributing to fewer relapses.
Importantly, no serious side effects were reported during the study, which adds to the potential appeal of using EPA as a treatment option. Overall, our findings suggest that EPA could be a useful component in the management of UC, helping patients achieve and sustain symptom-free periods.
Throughout the study, we tracked levels of calprotectin in fecal samples, a marker indicating inflammation in the intestines. Our goal was to see if EPA could lead to a significant reduction in these levels, as well as maintain remission from symptoms. The results were promising—after six months, we found that those taking EPA had lower calprotectin levels, suggesting less inflammation and contributing to fewer relapses.
Importantly, no serious side effects were reported during the study, which adds to the potential appeal of using EPA as a treatment option. Overall, our findings suggest that EPA could be a useful component in the management of UC, helping patients achieve and sustain symptom-free periods.
9
Eicosapentaenoic Acid Benefits UC Patients
We explored how eicosapentaenoic acid (EPA) affects patients with ulcerative colitis (UC), specifically looking at its impact on inflammation, colon differentiation, and gut bacteria. In this pilot study, we enrolled twenty patients who had long-standing UC yet were in stable clinical remission. Each participant received a daily supplement of EPA for 90 days, while we tracked changes in their condition.
Throughout the study, we measured mucosal inflammation using various scoring systems and assessed changes in specific markers related to colon health. We found that EPA supplementation significantly reduced levels of fecal calprotectin—a marker of inflammation—and improved both endoscopic and histological indicators of inflammation in the intestines. Additionally, we observed increases in beneficial markers that promote healing and maintain a healthy gut lining.
Perhaps one of the more exciting outcomes was how EPA influenced the balance of gut bacteria, partially restoring a healthier microbiota composition, which is often disrupted in UC patients. Overall, our findings suggest that EPA supplementation is a promising adjunct treatment for managing UC, as it helps reduce inflammation, supports gut cell health, and alters gut microbiota favorably.
Throughout the study, we measured mucosal inflammation using various scoring systems and assessed changes in specific markers related to colon health. We found that EPA supplementation significantly reduced levels of fecal calprotectin—a marker of inflammation—and improved both endoscopic and histological indicators of inflammation in the intestines. Additionally, we observed increases in beneficial markers that promote healing and maintain a healthy gut lining.
Perhaps one of the more exciting outcomes was how EPA influenced the balance of gut bacteria, partially restoring a healthier microbiota composition, which is often disrupted in UC patients. Overall, our findings suggest that EPA supplementation is a promising adjunct treatment for managing UC, as it helps reduce inflammation, supports gut cell health, and alters gut microbiota favorably.
References
- Ioannidis O, Cheva A, Varnalidis I, Koutelidakis I, Papaziogas V, et al. The Combined Administration of Eicosapentaenoic Acid (EPA) and Gamma-Linolenic Acid (GLA) in Experimentally Induced Colitis: An Experimental Study in Rats. J Clin Med. 2024;13. doi:10.3390/jcm13226661
- Dai Z, Wang Q, He B, Shi F, Chen W, et al. Causal association of plasma -3 PUFA with peptic ulcer disease: a two-sample Mendelian randomisation study. Br J Nutr. 2024;132:1014. doi:10.1017/S0007114524001752
- El Mahdy RN, Nader MA, Helal MG, Abu-Risha SE, Abdelmageed ME. Eicosapentaenoic acid mitigates ulcerative colitis-induced by acetic acid through modulation of NF-κB and TGF-β/ EGFR signaling pathways. Life Sci. 2023;327:121820. doi:10.1016/j.lfs.2023.121820
- Abdelsameea AA, Alsemeh AE, Alabassery N, Samy W, Fawzy A, et al. Icosapent ethyl alleviates acetic acid-induced ulcerative colitis via modulation of SIRT1 signaling pathway in rats. Int Immunopharmacol. 2023;115:109621. doi:10.1016/j.intimp.2022.109621
- Pagan JD, Hauss AA, Pagan EC, Simons JL, Waldridge BM. Long-chain polyunsaturated fatty acid supplementation increases levels in red blood cells and reduces the prevalence and severity of squamous gastric ulcers in exercised Thoroughbreds. J Am Vet Med Assoc. 2022;260:S121. doi:10.2460/javma.22.06.0275
- Ontoria-Oviedo I, Amaro-Prellezo E, Castellano D, Venegas-Venegas E, González-Santos F, et al. Topical Administration of a Marine Oil Rich in Pro-Resolving Lipid Mediators Accelerates Wound Healing in Diabetic Mice through Angiogenesis and Macrophage Polarization. Int J Mol Sci. 2022;23. doi:10.3390/ijms23179918
- Seth N, Chopra D, Lev-Tov H. Fish Skin Grafts with Omega-3 for Treatment of Chronic Wounds: Exploring the Role of Omega-3 Fatty Acids in Wound Healing and A Review of Clinical Healing Outcomes. Surg Technol Int. 2022;40:38.
- Fang J, Zhang Z, Cheng Y, Yang H, Zhang H, et al. EPA and DHA differentially coordinate the crosstalk between host and gut microbiota and block DSS-induced colitis in mice by a reinforced colonic mucus barrier. Food Funct. 2022;13:4399. doi:10.1039/d1fo03815j
- Zhang Z, Xue Z, Yang H, Zhao F, Liu C, et al. Differential effects of EPA and DHA on DSS-induced colitis in mice and possible mechanisms involved. Food Funct. 2021;12:1803. doi:10.1039/d0fo02308f
- McDaniel JC, Rausch J, Tan A. Impact of omega-3 fatty acid oral therapy on healing of chronic venous leg ulcers in older adults: Study protocol for a randomized controlled single-center trial. Trials. 2020;21:93. doi:10.1186/s13063-019-3970-7
- Tan A, Sullenbarger B, Prakash R, McDaniel JC. Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study. Prostaglandins Leukot Essent Fatty Acids. 2018;132:23. doi:10.1016/j.plefa.2018.03.010
- Scaioli E, Sartini A, Bellanova M, Campieri M, Festi D, et al. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2018;16:1268. doi:10.1016/j.cgh.2018.01.036
- Prossomariti A, Scaioli E, Piazzi G, Fazio C, Bellanova M, et al. Short-term treatment with eicosapentaenoic acid improves inflammation and affects colonic differentiation markers and microbiota in patients with ulcerative colitis. Sci Rep. 2017;7:7458. doi:10.1038/s41598-017-07992-1
- McDaniel JC, Szalacha L, Sales M, Roy S, Chafee S, et al. EPA + DHA supplementation reduces PMN activation in microenvironment of chronic venous leg ulcers: A randomized, double-blind, controlled study. Wound Repair Regen. 2017;25:680. doi:10.1111/wrr.12558
- Han YM, Park JM, Kang JX, Cha JY, Lee HJ, et al. Mitigation of indomethacin-induced gastrointestinal damages in fat-1 transgenic mice via gate-keeper action of ω-3-polyunsaturated fatty acids. Sci Rep. 2016;6:33992. doi:10.1038/srep33992
- Reddy KVK, Naidu KA. Oleic acid, hydroxytyrosol and n-3 fatty acids collectively modulate colitis through reduction of oxidative stress and IL-8 synthesis; in vitro and in vivo studies. Int Immunopharmacol. 2016;35:29. doi:10.1016/j.intimp.2016.03.019
- Ariturk LA, Cilingir S, Kolgazi M, Elmas M, Arbak S, et al. Docosahexaenoic acid (DHA) alleviates inflammation and damage induced by experimental colitis. Eur J Nutr. 2024;63:2801. doi:10.1007/s00394-024-03468-x
- Sánchez-Trigueros MI, Martínez-Vieyra IA, Pineda-Peña EA, Castañeda-Hernández G, Perez-Cruz C, et al. Role of antioxidative activity in the docosahexaenoic acid's enteroprotective effect in the indomethacin-induced small intestinal injury model. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:4275. doi:10.1007/s00210-023-02881-z
- Khoshnood S, Negahdari B, Kaviar VH, Sadeghifard N, Abdullah MA, et al. Amoxicillin-docosahexaenoic acid encapsulated chitosan-alginate nanoparticles as a delivery system with enhanced biocidal activities against and improved ulcer healing. Front Microbiol. 2023;14:1083330. doi:10.3389/fmicb.2023.1083330
- Zha R, Ge E, Guo L, Gao Q, Lin Q, et al. A newly identified polyunsaturated macamide alleviates dextran sulfate sodium-induced colitis in mice. Fitoterapia. 2021;152:104916. doi:10.1016/j.fitote.2021.104916
- Pham TL, Bazan HEP. Docosanoid signaling modulates corneal nerve regeneration: effect on tear secretion, wound healing, and neuropathic pain. J Lipid Res. 2021;62:100033. doi:10.1194/jlr.TR120000954
- Nakanishi M, Matz A, Klemashevich C, Rosenberg DW. Dietary Walnut Supplementation Alters Mucosal Metabolite Profiles During DSS-Induced Colonic Ulceration. Nutrients. 2019;11. doi:10.3390/nu11051118
- Ungaro F, Tacconi C, Massimino L, Corsetto PA, Correale C, et al. MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces Colitis in Mice. Gastroenterology. 2017;153:1363. doi:10.1053/j.gastro.2017.07.048
- Nagai K, Matsumaru K, Hirai I, Takae Y, Andoh K. New therapy using omega-3-Acid ethyl esters for decubitus ulcers and stasis dermatitis: a case report. Iran Red Crescent Med J. 2014;16:e19500. doi:10.5812/ircmj.19500
- Köhnke T, Gomolka B, Bilal S, Zhou X, Sun Y, et al. Acetylsalicylic Acid reduces the severity of dextran sodium sulfate-induced colitis and increases the formation of anti-inflammatory lipid mediators. Biomed Res Int. 2013;2013:748160. doi:10.1155/2013/748160
